Christine A. Poon net worth and biography

Christine Poon Biography and Net Worth

Christine A. Poon has been a director of the Company since 2010. Ms. Poon is a professor in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004 and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.

What is Christine A. Poon's net worth?: The estimated net worth of Christine A. Poon is at least $1.43 million as of August 23rd, 2023. Ms. Poon owns 2,037 shares of Regeneron Pharmaceuticals stock worth more than $1,429,668 as of December 21st. This net worth approximation does not reflect any other assets that Ms. Poon may own. Learn More about Christine A. Poon's net worth.
How do I contact Christine A. Poon?: The corporate mailing address for Ms. Poon and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Christine A. Poon's contact information.
Has Christine A. Poon been buying or selling shares of Regeneron Pharmaceuticals?: Christine A. Poon has not been actively trading shares of Regeneron Pharmaceuticals during the last ninety days. Most recently, Christine A. Poon sold 12,280 shares of the business's stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $839.97, for a transaction totalling $10,314,831.60. Following the completion of the sale, the director now directly owns 2,037 shares of the company's stock, valued at $1,711,018.89. Learn More on Christine A. Poon's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Christine A. Poon Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/23/2023	Sell	12,280	$839.97	$10,314,831.60	2,037
8/9/2022	Sell	15,000	$620.91	$9,313,650.00	1,872

Christine A. Poon Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.